Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

Abstract

Zojer (2020) Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

“…On individual scores, improvement cut-offs of 5-10 points (indicative of small improvements) and ≥10 points (indicative of medium to large improvements) from baseline were defined using previously established minimal important differences for MM. [18][19][20][21][22] The relevant scales were examined at both cut-offs as the number of improved patients per cycle and the percentage of improved patients of the total number per cycle.…”

Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life

“…Even though many clinical trials now include QOL as one of the key outcomes, its analysis is still not standardized, thereby hindering the comparability of results across trials and the literature [33,34]. Time to deterioration in QOL analyses rely, among other factors, on the threshold used to determine clinical relevance, with a change of 10 or more points on the GHS (in a single measurement) being one of the most common thresholds [33][34][35][36][37][38][39][40]. Although to a lesser extent, other thresholds have also been evaluated [41,42].…”

Patient‐reported pain severity and health‐related quality of life in patients with multiple myeloma in real world clinical practice

“…1 Patients with multiple myeloma (MM), especially those with relapsed/refractory disease, experience significantly more pain and poorer HRQoL (including physical, role, emotional, and social functioning) compared to an age-matched general population of the same geographical region. 2 Pain in MM is often due to myeloma bone disease, which is observed in more than 80% of patients during the course of their disease. Patients with earlier manifest or new bone disease experience discomfort or pain and a decrease in HRQoL.…”

“… 1 Patients with multiple myeloma (MM), especially those with relapsed/refractory disease, experience significantly more pain and poorer HRQoL (including physical, role, emotional, and social functioning) compared to an age‐matched general population of the same geographical region. 2 …”

“…With effective myeloma therapy, bone pain and other myeloma‐associated pain usually improves or resolves, 3 especially in patients with deep response to induction therapy and during maintenance phase. 2 Most patients unfortunately relapse after a variable length of time following successful induction therapy. A recent systematic review and meta‐analysis suggest that pain is particularly prominent during uncontrolled disease at start of initial therapy and at relapse.…”